Project Grant R37CA300321
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $645K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $399,129 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with a completion date of June 30, 2027. This award supports research to develop and evaluate improved cancer treatment methods through laboratory and clinical investigation. Specifically, the research leverages a DDX3 inhibitor called RK-33 to alter the metabolic tumor environment in...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a $591,419 project grant effective May 1, 2026 through April 30, 2031 under the Cancer Treatment Research program (CFDA 93.395) to develop low molecular weight (LMW) theranostic agents targeting multiple myeloma (MM). The research aims to create a first-in-class peptide-based theranostic pair that targets Cluster of Differentiation 38 (CD38) protein, which is uniformly and densely...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $410,545 Project Grant through the Cancer Treatment Research program (CFDA 93.395) to The Research Foundation for the State University of New York to conduct a two-year research initiative (May 1, 2026 – April 30, 2028) addressing monomethyl auristatin E (MMAE)-induced peripheral neuropathy in antibody-drug conjugate (ADC) cancer therapy. The research focuses on identifying novel signaling pathways and evaluating the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant totaling $144,193 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 4, 2025, with a completion date of August 31, 2030. This award provides protected salary support for Dr. Preethi Korangath, a Laboratory Research Specialist in Dr. Robert Ivkov's laboratory, to advance research in cancer detection and treatment technologies. Dr. Korangath will...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant totaling $162,080 under the Cancer Research Manpower program (CFDA 93.398) on December 27, 2025, with a completion date of June 30, 2028. Dr. Komatsu's laboratory is conducting research to visualize and characterize B cell infiltration and aggregation within the tumor microenvironment, with particular focus on the role of high endothelial venules (HEVs) as critical gateways for...
- Federal Grant Award Summary The National Cancer Institute awarded a $542,644 Project Grant to The Washington University (Office of Sponsored Research Services) under the Cancer Treatment Research program (CFDA 93.395), effective April 1, 2026, through March 31, 2031. This five-year research initiative focuses on developing radiation-guided antibody-drug conjugates (ADCs) for non-small cell lung cancer (NSCLC) treatment. The research leverages a breakthrough discovery identifying...
- Federal Grant Award Summary The University of Michigan's Regents received a $646,671 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective May 15, 2026 through April 30, 2031. This research initiative focuses on developing and characterizing novel antibody-drug conjugate (ADC) therapeutics designed to maximize immunogenic cell death and immune activation for cancer treatment. The project addresses a critical clinical gap...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $510,431 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2025 through June 30, 2030. This award supports fundamental research investigating the mechanisms of metastatic recurrence and therapeutic resistance in melanoma, with particular emphasis on understanding how aging influences tumor dormancy and the microenvironment. The research examines Wnt signaling...